Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption
Background: Sorafenib (SOR) is an oral, potent, selective, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used as the first-line therapy for advanced hepatocellular carcinoma (HCC). Baicalin (BG) is used as adjuvant therapy for hepatitis, which accounts for the le...
Enregistré dans:
Auteurs principaux: | Jingyao Wei, Ruijuan Liu, Jiali Zhang, Shuaibing Liu, Dan Yan, Xueqian Wen, Xin Tian |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4a48cab5eb4c44fbbdb5dd4acb8b1158 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
DETERMINATION OF CHLOROGENIC ACID, BAICALIN AND FORSYTHIN IN SHUANGHUANGLIAN PREPARATIONS BY HPLC-DAD
par: YANG,LI, et autres
Publié: (2012) -
Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability
par: Yin J, et autres
Publié: (2017) -
MiRNA-200b reverses drug resistance of hepatocellular carcinoma HepG2 cells to sorafenib and its underlying mechanism
par: DENG Yong, et autres
Publié: (2021) -
Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage
par: Bao Zheng, et autres
Publié: (2021) -
Preparation, Characterization and in vivo Study of Borneol-Baicalin-Liposomes for Treatment of Cerebral Ischemia-Reperfusion Injury
par: Zhang Y, et autres
Publié: (2020)